Method for preparing tilmicosin preparation

Abstract

The invention discloses a method for preparing a tilmicosin preparation. The method comprises the following steps: taking polyethylene glycol 6000 as a carrier, adding an anionic surfactant having a carrier mass of 1 to 3%, and heating the materials in a constant-temperature water bath at 60 DEG C to completely melt the material, adding a tilmicosin raw material to the complete melting with stirring, wherein the drug loading ratio is 1:2 by mass, and then quickly pouring the material into a pre-cooled stainless steel container, solidifying the product in a refrigerator at -20 DEG C, drying theproduct in a drying oven at 35 to 40 DEG C, and finally grinding the material through a sieve of 80 meshes to obtain a finished product. The method solves the problem that the tilmicosin preparationin the prior art is insoluble in water, bitter in taste and low in bioavailability, the tilmicosin preparation capable of masking bitterness, being soluble in water and having high bioavailability isprepared by a solid dispersion technology, the tilmicosin preparation is convenient for drinking water and can treat diseases in time, which can bring more convenience and benefits to the breeding industry.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a preparation method of a tilmicosin preparation. Background technique [0002] Tilmicosin is a new type of macrolide antibiotics semi-synthesized from tylosin for livestock and poultry. It has good inhibitory effect on Gram-positive bacteria and some Gram-negative bacteria, mycoplasma, spirochetes, etc. , It has stronger antibacterial activity than tylosin against Actinomyces pleuropneumoniae and Pasteurella, and has no cross-resistance with commonly used clinical antibiotics. Clinically, it is mainly used for animal respiratory diseases and mastitis of lactating animals, especially in the treatment of porcine respiratory syndrome and porcine reproductive and respiratory syndrome. However, tilmicosin has a certain degree of irritation, and tilmicosin is mainly administered by oral administration and subcutaneous injection, especially for pigs, which limits its clinical application in...

AI Technical Summary

Problems solved by technology

However, tilmicosin targets alveolar macrophages, which itself has the effect of targeted therapy, and for some acute diseases, sustained-release preparations cannot play a role in timely treatment. Most of the techniques require the addition of organic reagents, and the dosage Larger, higher cost, and sometimes difficult to remove, polluting the environment. At present, these new preparation technologies have not been applied in actual production

Images